ArticleMolecular medicine reports2026
Sedanolide alleviates LPS‑induced depressive‑like behaviors by modulating the C3a/C3aR signaling axis and microglial glycolysis.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of ~30% of patients with depression do not respond to pharmacological treatment. Sedanolide (SD) is a compound derived from Chinese medicinal herbs and has structural features associated with anti‑inflammatory activity. However, its effect on depressive disorders remains unclear. The present study aimed to examine the therapeutic effects of SD in lipopolysaccharide (LPS)‑induced depressive disorder and to investigate the underlying mechanisms. An LPS‑induced male mouse model of depressive‑like behavior was used to evaluate the therapeutic effect and underlying mechanisms of SD. The mRNA levels of pro‑inflammatory cytokines and the activation state of microglia in the medial prefrontal cortex (mPFC) were assessed. In addition, high‑throughput RNA sequencing was performed as an unbiased transcriptomic screen to identify differentially expressed genes. Western blotting and ELISA assays were then used to validate the expression and activation levels of key candidate molecules within the identified pathways. BV‑2 cell line was utilized to assess the aerobic glycolysis
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.